• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of July 8


The Center for Biosimilars® recaps the top stories for the week of July 8, 2019.


Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 8, 2019.

Number 5: An advocacy organization for patients with breast cancer said recently that it wants to provide education about the potential of biosimilars to reduce costs and provide more treatment options.

Number 4: Biocon is facing yet another setback after the FDA issued a new Form 483 for its insulin facility.

Number 3: New research shows a significant association between drug makers' payments to prescribers and Medicare spending on Humira and Cimzia in inflammatory bowel disease.

Number 2: A judge has vacated the Trump administration’s rule requiring the disclosure of wholesale acquisition costs for drugs in direct-to-consumer television advertising.

Number 1: Samsung Bioepis has gained an updated label for its biosimilar adalimumab, Imraldi, referencing Humira. The biosimilar is now approved for storage in nonrefrigerated conditions for up to 28 days.

Finally, last week, our e-newsletter asked whether you think that regulating patent settlements would incentivize companies to create patent thickets.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.